Hologic Inc. announced unaudited consolidated earnings results for the first quarter ended December 24, 2011. First quarter fiscal 2012 revenues totaled $472.7 million, an increase of 9.3% compared to revenues of $432.6 million in the first quarter of fiscal 2011. This increase resulted from growth in revenues in all four of its operating segments, primarily from: (i) growth in Breast Health revenues of $20.0 million, or 10.2%, driven by a $14.1 million, or 10.9%, increase in product revenues and a $5.9 million, or 9.0%, increase in service revenues; (ii) an increase in Diagnostics revenues of $15.0 million, or 10.8%, primarily due to growth in ThinPrep revenues from the acquisition of TCT International Co. Ltd. (TCT) in Beijing, China on June 1, 2011 and strong growth in sales of its Cervista HPV tests; (iii) an increase in GYN Surgical revenues of $2.9 million, or 3.8%, related to contributions from the MyoSure hysteroscopic tissue removal (MyoSure) system, partially offset by a decrease in NovaSure endometrial ablation (NovaSure) system sales; and (iv) an increase in Skeletal Health revenues of $2.3 million, or 10.3%, primarily due to an increase in bone densitometry product sales. For the first quarter of fiscal 2012, Hologic reported net income of $20.8 million, or $0.08 per diluted share, compared with net income of $10.9 million, or $0.04 per diluted share, in the first quarter of fiscal 2011. The company's non-GAAP adjusted net income increased 12.7% to $90.0 million, or $0.34 per diluted share, in the first quarter of fiscal 2012 compared to $79.9 million, or $0.30 per diluted share, in the prior year. The company provided earnings guidance for the second quarter ending March 24, 2012. The company's guidance reflects its current core products, including revenues from its approved/cleared products and its recently acquired businesses, but does not reflect any revenue or earnings from future acquisitions, if any. The company expects second quarter fiscal 2012 revenues of $470 to $475 million. This primarily reflects an increase in revenues related to its fiscal 2011 acquisitions, the ramp-up of new products including the Dimensions and MyoSure systems, and an overall strengthening in each of the company's operating segments. Year-over-year, this represents an expected increase in revenues of 7% to 8% over second quarter fiscal 2011 revenues of $438.7 million. The company expects non-GAAP adjusted EPS to be approximately $0.33. The company expects gross margins of approximately 62% to 62.5% on a non-GAAP basis and non-GAAP interest expense to be approximately $10 million, excluding $19 million of noncash interest expense related to its convertible. The company's non-GAAP effective tax rate is expected to be approximately 34% and expects non-GAAP earnings per diluted share to be approximately $0.33 on diluted shares outstanding of $267 million. The company revised earnings guidance for the year ending September 29, 2012. The company is reaffirming fiscal 2012 revenue guidance of $1.9 billion to $1.925 billion. Year-over-year, this represents an expected increase in revenues of 6% to 8% over fiscal 2011 revenues of $1.79 billion. This primarily reflects an increase in revenues related to the company's fiscal 2011 acquisitions and, to a lesser extent, increases in the Breast Health, GYN Surgical and Diagnostics segments. The company is increasing non-GAAP adjusted EPS guidance by $0.01 to approximately $1.36 to $1.38. Turning to the cash flow guidance, the company is reaffirming its free cash flow expectation of approximately $400 million to $425 million, which continues to be driven primarily by its operating earnings. As capital expenditures are not a big part of the company's business and it is expecting steady CapEx of $50 million and depreciation of approximately $65 million for the year.